betadex has been researched along with Kidney-Diseases* in 2 studies
2 other study(ies) available for betadex and Kidney-Diseases
| Article | Year |
|---|---|
β-Cyclodextrin counteracts obesity in Western diet-fed mice but elicits a nephrotoxic effect.
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. The multi-organ effects of obesity have been linked to ectopic lipid accumulation. Thus, there is an urgent need to tackle the obesity crisis by developing effective lipid-lowering therapies. 2-hydroxypropyl-β-Cyclodextrin (2HP-β-CD) has been previously shown to reduce lysosomal cholesterol accumulation in a murine model of Niemann Pick Type C (NPC) disease. Using a murine model of Western diet-induced obesity (DIO), we report the effects of 2HP-β-CD in counteracting weight gain, expansion of adipose tissue mass and ectopic lipid accumulation. Interestingly, DIO caused intracellular storage of neutral lipids in hepatic tissues and of phospholipids in kidneys, both of which were prevented by 2HP-β-CD. Importantly, this report brings attention to the nephrotoxic effects of 2HP-β-CD: renal tubular damage, inflammation and fibrosis. These effects may be overlooked, as they are best appreciated upon assessment of renal histology. Topics: Animals; beta-Cyclodextrins; Cholesterol; Diet, Western; Disease Models, Animal; Hypolipidemic Agents; Kidney; Kidney Diseases; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phospholipids; Triglycerides | 2019 |
Evaluation of cholesterol depletion as a marker of nephrotoxicity in vitro for novel β-cyclodextrin derivatives.
Cyclodextrins (CDs) have been shown to improve physicochemical and biopharmaceutical properties of drugs when low solubility and low safety limit their use in the pharmaceutical field. Recently, we have developed new multi-substituted-β-CDs, hydroxypropyl-sulfobutyl ether-β-cyclodextrin (HPn-SBEm-β-CD). HPn-SBEm-β-CD exhibit low hemolysis, good solubility, strong inclusion ability, and an appropriate average molecular weight. In this study, we chose two products of HPn-SBEm-β-CD (HP(3)-SBE(2)-β-CD and HP(2)-SBE(3)-β-CD) and compared their effects to sulfobutyl ether-β-cyclodextrin (SBE(7)-β-CD), methyl-β-cyclodextrin (M-β-CD) and 2,6-di-O-methyl-β-cyclodextrin (DM-β-CD). We evaluated viability, membrane damage, induction of apoptosis and necrosis, cholesterol depletion, and morphological changes in human embryonic kidney 293A cells (HEK293A) in vitro. CDs caused a reduction of cell viability and increased LDH levels in a concentration-dependent manner. The effect of HP(3)-SBE(2)-β-CD or HP(2)-SBE(3)-β-CD on cell viability, membrane damage, and the induction of apoptosis and necrosis resembled that of SBE(7)-β-CD, whereas the effects were significantly lower for M-β-CD or DM-β-CD. HP(3)-SBE(2)-β-CD and HP(2)-SBE(3)-β-CD exhibited morphological changes at high concentrations. In conclusion, the results showed that cholesterol depletion may be as a marker for evaluating the cytotoxicity of novel β-CD derivatives. These results will provide useful information for HPn-SBEm-β-CD as a promising safe adjuvant for intravenous administration in the future. Topics: Apoptosis; beta-Cyclodextrins; Biomarkers; Cell Membrane; Cell Nucleus; Cell Survival; Cholesterol; Flow Cytometry; HEK293 Cells; Humans; Kidney; Kidney Diseases; L-Lactate Dehydrogenase; Necrosis | 2011 |